We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Soft X-Ray Tomography 3D Scans Show How Cells Respond to SARS-CoV-2 Infection and to Possible Treatments

By HospiMedica International staff writers
Posted on 28 Feb 2022
Image: Digital images of cells infected with SARS-CoV-2 created from soft X-ray tomography (Photo courtesy of Berkeley Lab)
Image: Digital images of cells infected with SARS-CoV-2 created from soft X-ray tomography (Photo courtesy of Berkeley Lab)

An extremely fast new 3D imaging method can show how cells respond to SARS-CoV-2 infection and to possible treatments.

Researchers from Berkeley Lab (Berkeley, CA, USA) and Heidelberg University (Heidelberg, Germany) have cranked up the speed of imaging infected cells using soft X-ray tomography (SXT), a microscopic imaging technique that can generate incredibly detailed, three-dimensional scans. Their approach takes mere minutes to gather data that would require weeks of prep and analysis with other methods, giving scientists an easy way to quickly examine how our cells’ internal machinery responds to SARS-CoV-2, or other pathogens, as well as how the cells respond to drugs designed to treat the infection.

SXT was developed at Berkeley Lab in the early 2000s to fill in the gaps left by other cellular imaging techniques and is currently offered to investigators worldwide even as the researchers continue to refine the approach. As part of a study, the researchers performed SXT on human lung cell samples. The team carefully infected the cells with SARS-CoV-2 and then chemically fixed them with aldehyde-based compounds – a process that kills cells and preserves them, immobilized, in their last living state (and also inactivates any remaining viral particles) – at six and 24 hours post-infection.

The entire team was jubilant when the resulting 3D images had the same level of exquisite detail and clarity that SXT is known for, despite the chemical fixation done to the cells. The takeaway is that their approach will allow many labs to safely image infected cells without the inherent risks – and corresponding required safety protocols – of working with live infected cells. Upon conducting the tomography sessions and image analysis, the researchers were pleasantly surprised to see how SXT captured changes to different organelles within the lung cells at very high resolution after very little time spent on sample preparation and without use of stains or labeling. These additional steps are often needed to generate cell maps wherein the different internal components are easily distinguishable.

Now that they’ve demonstrated the potential of using whole-cell SXT to safely image virus-infected cells, the researchers believe that their findings will help the global scientific community study COVID-19 and potentially other diseases. The team is already putting the technique to good use and has begun using whole-cell SXT to examine how human cells respond to several experimental COVID-19-treating drugs. They hope the rapid turnaround for results will help expedite the drug development process, getting additional effective treatments on the market sooner. They also plan to use the technology to understand the progress of infections caused by other viral agents.

“Prior to our imaging technique, if one wanted to know what was going on inside a cell, and to learn what changes had occurred upon an infection, they'd have to go through the process of fixing, slicing, and staining the cells in order to analyze them by electron microscopy. With all the steps involved, it would take weeks to get the answer. We can do it in a day,” said project co-lead Carolyn Larabell, a Berkeley Lab faculty scientist in the Biosciences Area. “So, it really speeds up the process of examining cells, the consequences to infection, and the consequences of treating a patient with a drug that may or may not cure or prevent the disease.”

Related Links:
Berkeley Lab 
Heidelberg University 

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Trocar
TAN RoTaLock Trocar
New
Hospital Data Analytics App
Alarm History Analytics

Channels

Critical Care

view channel
Image: Researchers have unlocked the heart’s hidden geometry that could revolutionize ECG interpretation (Photo courtesy of KCL)

Discovery of Heart’s Hidden Geometry to Revolutionize ECG Interpretation

Electrocardiograms (ECGs) are one of the most widely used tools in diagnosing heart conditions, but their accuracy can be affected by natural variations in individual heart anatomy. Traditional ECG interpretation... Read more

Surgical Techniques

view channel
Image: For the first time, a fluorescent-guided nerve imaging agent has shown promise for use in humans (Photo courtesy of VUMC)

Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery

Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more